Testosterone Enanthate vs AndroGel: Long-Term Durability of Response

What "Long-Term Durability of Response" Actually Means in TRT

Long-term durability refers to whether a testosterone formulation continues to maintain serum testosterone in the eugonadal range (300 to 1,000 ng/dL per Endocrine Society guidelines) without dose escalation, receptor desensitization, or progressive loss of symptomatic benefit over months and years of use. Endocrine Society 2018 Clinical Practice Guideline defines treatment success as sustained levels in this window alongside patient-reported symptom improvement.

Why This Matters Clinically

Testosterone itself does not produce pharmacological tolerance the way opioids or benzodiazepines do. The pituitary-gonadal axis suppression that occurs on TRT is expected and intentional. What can erode over time is adherence (missed injections, forgotten gel applications) and absorption consistency (skin changes with gels, injection-site fibrosis with long-term IM dosing).

The Core Pharmacokinetic Difference

Testosterone enanthate is an esterified androgen with a half-life of approximately 4.5 days after intramuscular injection. A single 200 mg dose typically peaks at 800 to 1,100 ng/dL within 48 to 72 hours and falls to the low-normal or subtherapeutic range by day 10 to 14. This pharmacokinetic profile is well characterized in the FDA label for testosterone enanthate.

AndroGel 1.62% applied once daily reaches a pseudo-steady-state within 24 to 48 hours, with day-to-day variation of roughly 10 to 20% around the mean. The FDA-approved label for AndroGel 1.62% reports mean Cavg values of approximately 400 to 500 ng/dL at the 40.5 mg daily dose in the key registration trial (N=149). See the AndroGel prescribing information.

Evidence from the T-Trials: The Most Rigorous Long-Term Dataset

The Testosterone Trials (T-Trials) remain the largest placebo-controlled study of TRT in older hypogonadal men. Published in the New England Journal of Medicine in 2016, the coordinated network enrolled 790 men aged 65 or older (mean age 72) with confirmed serum testosterone <275 ng/dL and age-related symptoms. Snyder PJ et al., NEJM 2016.

What the T-Trials Used and Found

The T-Trials used AndroGel 1% titrated to target levels of 500 to 1,000 ng/dL. At 12 months, the testosterone group achieved a mean level of approximately 500 ng/dL vs. Roughly 230 ng/dL in the placebo arm. Key findings at 12 months included:

• Sexual Activity Trial: testosterone improved sexual desire and activity (P<0.001 vs. Placebo).
• Physical Function Trial: a modest but statistically significant improvement in 6-minute walk distance.
• Vitality Trial: small improvement in energy on the FACIT-Fatigue scale.
• Bone Trial (published separately, NEJM 2017, N=211): volumetric bone density increased by 7.5% at the spine and 4.1% at the hip vs. Placebo.

The T-Trials did not include a testosterone enanthate injection arm, which is a meaningful gap. They do, however, confirm that gel-based testosterone sustains therapeutic levels and drives measurable end-organ benefit over a full year in older men. That duration is the minimum benchmark any durable TRT strategy should clear.

Injection Data from Supportive Trials

The TESTOSTERONE trial (Aversa et al., 2010, N=70) compared testosterone undecanoate (a long-acting injectable cousin of enanthate) to testosterone gel over 18 months and found that both arms maintained testosterone in the normal range throughout, with no meaningful difference in final symptom scores on the IIEF. Aversa A et al., J Androl 2010.

A 2-year observational registry study (Haider et al., Andrologia 2014, N=261) following men on testosterone undecanoate injections found that mean serum testosterone remained at 15.8 nmol/L (approximately 455 ng/dL) from months 6 through 24 without dose escalation in 87% of patients. Haider A et al., Andrologia 2014. While undecanoate differs from enanthate in ester length and dosing interval, both belong to the injectable esterified testosterone class and share the same steroidogenic pathway once the ester is cleaved.

Pharmacokinetic Stability: Injections vs. Gel Over Time

Enanthate: Peaks, Troughs, and What They Mean Symptomatically

The bi-weekly 200 mg enanthate schedule is the most prescribed injectable regimen in the United States. Peak testosterone 48 hours post-injection may reach 1,200 to 1,500 ng/dL in some men, falling to 200 to 300 ng/dL just before the next dose. That trough is below the eugonadal threshold defined by both the Endocrine Society and the American Urological Association.

Switching to weekly 100 mg dosing cuts the peak-to-trough swing roughly in half, keeping most patients within 400 to 900 ng/dL throughout the week. Bhasin S et al., J Clin Endocrinol Metab 2006 confirmed that weekly injections of 100 mg enanthate maintained mid-normal levels in the majority of participants over 20 weeks. This is the schedule the HealthRX clinical team recommends for most injection candidates.

Gel: Absorption Variability Is the Main Durability Risk

AndroGel absorption is affected by skin hydration, application site, showering timing, and body surface area. In a subset analysis of the T-Trials, approximately 20% of men required dose uptitration from the starting 50 mg/day dose to maintain target levels. This is not tolerance; it is pharmacokinetic variability. Men with thicker skin, lower dermal vascularity, or inconsistent application technique absorb less gel per application over time.

Gel adherence data from real-world pharmacy claims (Bolge SC et al., J Med Econ 2013, N=2,122 TRT users) showed a 12-month medication possession ratio of 0.72 for topical testosterone vs. 0.84 for injectable testosterone, meaning gel users were more likely to miss doses over a year of therapy. Bolge SC et al., J Med Econ 2013.

Head-to-Head Stability Summary

| Parameter | Testosterone Enanthate (weekly 100 mg) | AndroGel 1.62% (40.5 mg/day) | |---|---|---| | Peak serum testosterone | 700 to 1,000 ng/dL | 450 to 600 ng/dL | | Trough serum testosterone | 350 to 500 ng/dL | 350 to 550 ng/dL | | Intra-cycle variability | Moderate (weekly swing) | Low (day-to-day) | | Absorption predictability | High (IM depot) | Moderate (skin-dependent) | | Real-world 12-month adherence | ~84% MPR | ~72% MPR | | FDA-boxed warning | No | Yes (secondary exposure) |

Bone Density, Cardiovascular Markers, and Body Composition: Does the Delivery Route Matter?

Bone Mineral Density

The T-Trials bone sub-study (Snyder PJ et al., NEJM 2017, N=211) showed gel-based TRT increased lumbar spine volumetric BMD by 7.5% at 12 months, significant vs. Placebo (P<0.001). Snyder PJ et al., NEJM 2017.

For injectable testosterone, a 3-year RCT by Amory et al. (J Clin Endocrinol Metab 2004, N=60) demonstrated that 200 mg testosterone enanthate every 2 weeks increased lumbar spine BMD by 8.0% and femoral neck BMD by 5.3% over 36 months vs. Baseline, with no attenuation of effect in the third year. Amory JK et al., J Clin Endocrinol Metab 2004. The mechanism driving BMD improvement is the aromatization of testosterone to estradiol at the bone level, which occurs regardless of delivery route once circulating testosterone is in the normal range.

Cardiovascular Risk Profile

The 2023 TRAVERSE trial (N=5,246, mean follow-up 33 months) is the definitive cardiovascular safety dataset for TRT. Using a testosterone gel formulation, TRAVERSE found no significant difference in major adverse cardiovascular events (MACE) between testosterone and placebo (HR 0.96; 95% CI 0.78 to 1.17). Lincoff AM et al., NEJM 2023. The FDA accepted these data to update TRT labeling in 2024. No equivalent MACE-powered RCT has been conducted for testosterone enanthate injections specifically, though mechanistic data suggest comparable risk profiles once equivalent testosterone exposure is achieved.

Lean Mass and Fat Mass

A meta-analysis by Bhasin et al. (J Clin Endocrinol Metab 2001, N=29 trials) found testosterone therapy increased lean body mass by a mean of 1.7 kg and decreased fat mass by 1.6 kg across injectable and gel formulations, with no statistically significant difference between delivery routes when serum testosterone targets were matched. Bhasin S et al., J Clin Endocrinol Metab 2001.

Switching Testosterone Enanthate to AndroGel (or Vice Versa)

When a Switch Makes Clinical Sense

Switching from enanthate to AndroGel is typically driven by:

1. Needle phobia or injection-site reactions (lipohypertrophy, hematoma, post-injection pain).
2. Occupational restrictions on self-injection (certain law enforcement, aviation, or DOT-regulated roles).
3. Patient preference for a needle-free daily routine.

Switching from AndroGel to enanthate is more commonly driven by cost (generic enanthate runs roughly $20, $40 per month vs. $300, $600 for branded AndroGel without insurance), transfer concerns at home, or inadequate absorption with gel.

How to Execute the Switch Safely

The Endocrine Society 2018 guideline states: "Clinicians should individualize testosterone formulation based on the patient's preference, pharmacokinetics, and cost, and should re-check serum testosterone 3 months after any formulation change to confirm therapeutic levels." Bhasin S et al., J Clin Endocrinol Metab 2018.

From a practical standpoint:

• Gel to enanthate: Start the first injection on the day the patient would have applied the next gel dose. Check a mid-cycle trough (day 6 of a weekly schedule) at the 6-week mark.
• Enanthate to gel: Begin daily gel application the morning after the last injection dose would have been due. Obtain a steady-state level after 2 weeks of consistent daily use.

Serum testosterone should be rechecked at 6 weeks and 3 months after the switch. Hematocrit should be monitored, as both formulations can raise red cell mass, particularly in older men. The AUA guideline recommends checking hematocrit at baseline, 3 months, and annually once stable. American Urological Association 2022 Guideline on Testosterone Deficiency.

What to Expect Symptomatically After Switching

Men switching from enanthate to gel often report less mood variability and fewer libido fluctuations tied to the injection cycle, because the gel eliminates the supraphysiologic peak and the late-cycle trough. However, some men report feeling "less effective" on the gel, particularly in the first 4 to 6 weeks, because they no longer experience the high-normal peak. This is a perception effect, not a physiological loss of efficacy, provided steady-state levels are confirmed in the therapeutic range.

Men switching from gel to enanthate may notice a stronger androgenic response in the first 1 to 2 weeks post-injection, especially if their gel absorption was suboptimal. Erythrocytosis risk is slightly higher with injections due to the supraphysiologic peak stimulating erythropoietin production.

Cost, Convenience, and Real-World Adherence

Cost is a major driver of long-term durability in the real world. A patient who cannot afford their medication simply does not take it. Generic testosterone enanthate (200 mg/mL, 10 mL vial) is available at most pharmacies for $20, $45 per month using GoodRx discounts. Branded AndroGel 1.62% without insurance lists at approximately $500, $650 per month, though compounded testosterone gel from a 503B pharmacy can bring topical costs closer to $30, $60 per month.

The 2013 Bolge pharmacy claims study (N=2,122) cited above found that cost-related non-adherence was reported by 31% of gel users vs. 14% of injection users over 12 months. Cost-driven interruptions break hormonal continuity and allow hypogonadal symptoms to return, which patients may incorrectly attribute to "the medication stopping working."

Monitoring Protocol for Long-Term Durability

Both formulations require the same core monitoring schedule to confirm durable response:

• Baseline: Total testosterone (morning draw), LH, FSH, CBC, PSA, hematocrit, lipid panel.
• 6 weeks after initiation or formulation change: Total testosterone (morning draw for gel; mid-cycle trough for weekly enanthate injection).
• 3 months: Total testosterone, hematocrit, PSA.
• Annually: Full panel including CBC, metabolic panel, PSA, lipids.

For enanthate, the Endocrine Society recommends drawing the trough level just before the next injection is due, or the mid-cycle level (3 to 4 days post-injection for a weekly schedule) to avoid both supraphysiologic peaks and trough-level underestimates. For gel, draw at least 2 hours after the morning application and at least 24 hours after the last shower post-application.